抗VEGF及其受体分子靶向药物治疗肝癌机制的研究进展  

Advances of VEGF signalling pathway in hepatocellular carcinomar invasion and metastasis and therapy

作　　者：蓝雪灵 黄燕妮 朱敏敏 马平 董敏[1,2] LAN Xueling;HUANG Yanni;ZHU Minmin;MA Ping;DONG Min(School of Pharmacy,Guangxi Medical University,Nanning 530021,Guangxi,China;Beibu Gulf Marine Biomedical Precision Development and High Value Utilization Engineering Research Center,Guangxi Zhuang Autonomous Region,Nanning 530021,Guangxi,China;Guangxi Zhuang Autonomous Region Fangchenggang First People's Hospital,Fangchenggang 538021,Guangxi,China)

机构地区：[1]广西医科大学药学院,广西南宁530021 [2]广西壮族自治区北部湾海洋生物医药精准开发和高值利用工程研究中心,广西南宁530021 [3]广西壮族自治区防城港市第一人民医院,广西防城港538021

出　　处：《中国临床药理学与治疗学》2024年第6期707-714,共8页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：国家自然科学基金青年基金(81302859);广西自然科学基金面上(2021GXNSFAA196070,2018GXNSFAA050121);广西科技计划重点研发项目(2022AB14010);防城港市科技计划重点研发项目(AB22013006)。

摘　　要：肝细胞癌(hepatocellular carcinoma,HCC)的发生发展过程与肿瘤血管的形成密切相关。由血管内皮生长因子(VEGF)介导的血管生成是肿瘤产生免疫逃逸反应的主要驱动因素,VEGF与内皮细胞上血管内皮生长因子受体(vascularendothe-lial growth factor receptor2,VEGFR2)结合后,促进内皮细胞增殖和迁移,诱导肝癌发生血管改变,进而促进肝癌细胞生长。抗VEGF及其受体分子靶向药物是目前治疗肝癌的有效新手段。针对VEGF的单克隆抗体和靶向VEGF的小分子酪氨酸激酶抑制剂已显示出阻断其血管生成活性,缓解肿瘤微环境的抑制作用,最终达到消退肿瘤的作用。本文就VEGF/VEGFR抑制剂在肝癌治疗中的研究进展作一综述。The development of hepatocellular car-cinoma(HCC)is closely related to the formation of tumour blood vessels.VEGF-mediated angiogenesis is a major driver of the immune escape response in tumours.VEGF binds to vascular endothelial growth factor receptor2(VEGFR2)on endothelial cells,promoting endothelial cell proliferation and migration,inducing vascular changes in HCC,and thus promote the growth of hepatocellular carcino-ma cells.Anti-VEGF and its receptor-targeted mo-lecular drugs are currently effective new treat-ments for HCC.Monoclonal antibodies against VEGF and small-molecule tyrosine kinase inhibitors targeting VEGF have been shown to block its angio-genic activity,alleviate the inhibitory effect of the tumour microenvironment,and ultimately achieve tumour regression.This article provides a review of the research progress of VEGF/VEGFR inhibitors in HCC treatment.

关 键 词：VEGF/VEGFR抑制剂 肝细胞癌 信号通路 免疫疗法 

分 类 号：R968[医药卫生—药理学]